Scope
1 known investors
Scope Biosciences develops scopeDx, a CRISPR-Cas-based molecular diagnostic test for on-site detection of crop pathogens, offering PCR-level sensitivity with results in under an hour without a laboratory. It targets agricultural growers seeking early, pre-symptomatic disease detection to protect crop yields.